Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.61 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CHRNG | P07510 | 1/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CHRND | Q07001 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetoacetic Acid SCHEMBL28005292 | 0.85 | CES2 (0.46) | CES2CES1ACHEKMT2ARAB9A | |
| SCHEMBL28771713 | 0.83 | CES2 (0.57) | CES2CES1KMT2ARAB9AMEN1 | |
| SCHEMBL30255233 | 0.83 | CES2 (0.61) | CES2CES1KMT2ARAB9AMEN1 | |
| SCHEMBL5253742 | 0.83 | CES2 (0.61) | CES2CES1KMT2ARAB9AMEN1 | |
| SCHEMBL2273688 | 0.83 | CES2 (0.61) | CES2CES1KMT2ARAB9AMEN1 | |
| SCHEMBL246840 | 0.82 | ACHE (0.42) | CES2CES1ACHERAB9ANPC1 | |
| SCHEMBL4949504 | 0.82 | ACHE (0.42) | CES2CES1ACHEKMT2ARAB9A | |
| SCHEMBL4621038 | 0.82 | PIM1 (0.55) | CES2CES1ACHEKMT2AMEN1 | |
| SCHEMBL3502522 | 0.82 | KCNQ3 (0.46) | CES2CES1ACHEKCNQ3KCNQ2 | |
| SCHEMBL247898 | 0.81 | CES2 (0.59) | CES2CES1KMT2ARAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104844412-B | A kind of preparation method of 1,2,4-trifluoro-benzene | 浙江林江化工股份有限公司 | 2016-06-08 | — | — | CN | claimed |
| CN-102482297-B | Fluorine silicon ethyl-acetylene base pentacene compound and composition with and production and preparation method thereof | 3M INNOVATIVE PROPERTIES CO. (US) | 2015-12-09 | — | — | CN | claimed |
| CN-104844412-A | Preparation method of 1,2,4-trifluorobenzene | ZHEJIANG LINJIANG CHEMICAL CO LTD | 2015-08-19 | — | — | CN | claimed |
| CN-101244994-B | Novel method for producing 2,4,5-trifluoro benzene acetic acid | CHANGZHOU YABANG PHARMACEUTICAL CO LTD | 2013-02-13 | — | — | CN | claimed |
| CN-102482297-A | Fluorinated silylethynyl pentacene compounds and compositions and methods of making and using same | 3M INNOVATIVE PROPERTIES CO | 2012-05-30 | — | — | CN | claimed |
| JP-2184650-A | — | — | None | — | — | JP | disclosed |
| CN-117603048-A | Preparation method of ethyl 2,4, 5-trifluorobenzoyl acetate | 安徽森吉制药有限公司 | 2024-02-27 | — | — | CN | disclosed |
| CN-117088869-A | 3CL protease inhibitor and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-107406412-B | TGF-beta inhibitors | 里格尔药品股份有限公司 | 2021-07-16 | — | — | CN | disclosed |
| CN-107207531-B | Fused imidazole derivatives as TGF-beta inhibitors | 里格尔药品股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-105712945-B | 2-substituted oxy-5-methylsulfonyl aryl piperazine amide analogue and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| US-10441946-B2 | Linear alpha-olefin catalysts and preparation and use thereof | APALENE TECHNOLOGY CO., LTD. (HANGZHOU) (CN) | 2019-10-15 | — | — | US | disclosed |
| WO-1996004247-A1 | PROCESS FOR MAKING ANTIMICROBIAL COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1996-02-15 | — | — | WO | disclosed |
| EP-0365913-B1 | Substituted 2-aminothiazoles | BAYER AG (DE) | 1993-11-18 | — | — | EP | disclosed |
| US-5142092-A | Chemical intermediate for making fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-25 | — | — | US | disclosed |
| EP-0365914-B1 | FLUORINE-CONTAINING ACETOPHENONES OPTIONALLY HALOGENATED IN THE CH3-GROUP, AND THEIR PREPARATION FROM FLUORINATED BENZONITRILES | BAYER AG (DE) | 1992-07-22 | — | — | EP | disclosed |
| US-5104879-A | ANTIMYCOTICALLY ACTIVE SUBSTITUTED 2-AMINOTHIAZOLES | BAYER AKTIENGESELLSCHAFT (DE) | 1992-04-14 | — | — | US | disclosed |
| JP-H02184650-A | 2,4,5-TRIFLUOROACETOPHENONE, PRODUCTION THEREOF AND PRODUCTION OF 2,4,5-TRIFLUOROBENZOIC ACID | CENTRAL GLASS CO LTD | 1990-07-19 | — | — | JP | disclosed |
| EP-0365914-A2 | Fluorine-containing acetophenones optionally halogenated in the CH3-group, and their preparation from fluorinated benzonitriles | BAYER AG (DE) | 1990-05-02 | — | — | EP | disclosed |
| EP-0365913-A2 | Substituted 2-aminothiazoles | BAYER AG (DE) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441946-B2 | Linear alpha-olefin catalysts and preparation and use thereof | UBE2L3, COG8, ACSL3 | CES2 3635/4885CES1 3277/4885ACHE 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.